Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Satu Mustjoki, MD, PhD, Philippe Rousselot, MD, PhD, Sari Jalkanen, Msc, Anna Kreutzman, MSc, Teresa Melo, MD, Anna-Maria Lahesmaa, MSc, Sampsa Hautaniemi, PhD, Mathieu Molimard, MD, PhD, Richard Smykla, PhD, Francis Lee, PhD, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2010) 116 (21): 1204.

https://doi.org/10.1182/blood.V116.21.1204.1204

Published: 2010

Journal Articles

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Gary L Schieven, Rosemary Zhang, Sidney Pitt, Kelly McGlinchey, Krista Menard, Richard Smykla, Vojkan Susulic, Mei-Li Wen, Amy Wiebesiek, Robert Townsend, Francis Y. Lee

Blood (2009) 114 (22): 2198.

https://doi.org/10.1182/blood.V114.22.2198.2198

Published: 2009

Journal Articles

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Blood (2008) 112 (4): 1005–1012.

https://doi.org/10.1182/blood-2008-02-140665

Published: 2008

Includes: Supplemental data

Journal Articles

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, M.Sc., Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, Roger Luo, PhD, David Kan, B.Sc, Veeraswamy Manne, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Roberto Weinmann, PhD, Robert Kramer, PhD

Blood (2005) 106 (11): 1993.

https://doi.org/10.1182/blood.V106.11.1993.1993

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Rajeev Bhide, PhD, Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, B.Sc, Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, David Kan, B.Sc, Roger Luo, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Robert Wild, PhD, Robert Borzilleri, PhD, Louis Lombardo, PhD

Blood (2005) 106 (11): 1994.

https://doi.org/10.1182/blood.V106.11.1994.1994

Published: 2005

Journal Articles

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

Feng Roger Luo, Ph.D., Zheng Yang, Ph.D., Amy Camuso, B.S., Richard Smykla, B.S., Stephen Castenada, B.S., Christine Flefleh, B.S., Krista Fager, M.S., Ivan Inigo, B.S., David Kan, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, M.S., Robert Wild, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1987.

https://doi.org/10.1182/blood.V104.11.1987.1987

Published: 2004

Journal Articles

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Robert Wild, Ph.D., Stephen Castaneda, B.S., Christine Flefleh, B.S., Krista Fager, B.S., Ivan Inigo, B.S., David Kan, B.S., Richard Smykla, B.S., Amy Camuso, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, B.S., Feng Roger Luo, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.

Blood (2004) 104 (11): 1988.

https://doi.org/10.1182/blood.V104.11.1988.1988

Published: 2004

NARROW

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Email alerts

ASH Publications

American Society of Hematology

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only